What is Utah Medical Products's EV / EBITDA?

Utah Medical Products (UTMD) reported EV / EBITDA of 8× in Q1 2026.

What is the long-term trend for Utah Medical Products's EV / EBITDA?

Over 5 years (2020 to 2025), Utah Medical Products's EV / EBITDA has grown at a -11.9% compound annual growth rate (CAGR), from 12.3× to 6.5×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Utah Medical Products UTMD EV / EBITDA

EV / EBITDA at other companies

Becton, Dickinson and CompanyBDX

12.3×-6.5×

TFX

TeleflexTFX

26.8×+7.6×

The Cooper Companies, Inc.COO

17.2×+0.2×

IAR

Integra LifeSciencesIART

19.7×+3.6×

Merit Medical SystemsMMSI

14.2×-10.5×

PDE

Pro-Dex, Inc.PDEX

13.5×+0.5×

Other financials

Income statement

See full

Revenue$8.7M-10.2%

Gross profit$5.3M-4.6%

Operating income$2.6M-18.6%

Net income$2.6M-14.4%

EPS (diluted)$0.82-10.9%

Balance sheet

See full

Cash & equivalents$87.4M+4.9%

Total debt$210.0K—

Total equity$120.4M+2.8%

Total assets$124.4M+1.5%

Cash flow

See full

Operating cash flow$3.1M-30.4%

CapEx$130.0K-29.3%

Free cash flow$3.0M-30.4%

Valuation

See full

Market cap$219.63M+26.4%

Enterprise value$132.44M+42.5%

P/E20.3×+6.4×

P/S5.9×+1.4×

Profitability

See full

Gross margin57.9%-0.4pp

Operating margin28.8%-3.9pp

Net margin28.9%-4.1pp

FCF margin34.7%0.0pp

Returns & leverage

See full

Return on equity9.1%-1.4pp

Debt / equity0×—

Current ratio28.6×+6.3×

Where this comes from

Calculated from Utah Medical Products’s reported figures.

enterprise value/ebitda=8×

Based on the most recent quarter.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Utah Medical Products's EV / EBITDA?: Utah Medical Products (UTMD) reported EV / EBITDA of 8× in Q1 2026.
What is the long-term trend for Utah Medical Products's EV / EBITDA?: Over 5 years (2020 to 2025), Utah Medical Products's EV / EBITDA has grown at a -11.9% compound annual growth rate (CAGR), from 12.3× to 6.5×.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.